Orgenesis (ORGS) 10-Q 15 Oct 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Aug. 31, 2013	Oct. 14, 2013
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Aug-13
Trading Symbol	orgs
Entity Registrant Name	Orgenesis Inc.
Entity Central Index Key	1460602
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		51,144,621
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Aug. 31, 2013	Nov. 30, 2012
CURRENT ASSETS:
Cash and cash equivalents	$516,434	$347
Short term deposits	10,002	10,002
Prepaid expenses and Accounts receivable	56,626	28,249
Total current assets	583,062	38,598
FUNDS IN RESPECT OF RETIREMENT BENEFIT OBLIGATIONS	2,857	1,296
PROPERTY AND EQUIPMENT, NET	13,708	8,273
Total assets	599,627	48,167
CURRENT LIABILITIES:
Accounts payable	151,343	135,791
Accrued expenses	167,027	73,138
Employees and related payables	121,314	75,879
Related parties	42,362	42,362
Loan	258,333	0
Total current liabilities	740,379	327,170
LONG-TERM LIABILITIES
Warrants	1,161,956	0
Retirement benefit obligations	3,475	1,553
Total long term liabilities	1,165,431	1,553
Total liabilities	1,905,810	328,723
STOCKHOLDERS' DEFICIENCY:
Common stock of $0.0001 par value - authorized: 1,750,000,000 shares at August 31, 2013 and November 30, 2012; issued and outstanding: 51,144,621 and 49,117,903 shares at August 31, 2013 and November 30, 2012, respectively	5,114	4,912
Additional paid-in capital	7,648,402	4,850,348
Deficit accumulated during the development stage	-8,959,699	-5,135,816
Total Stockholders' deficiency	-1,306,183	-280,556
Total liabilities net of Stockholders' deficiency	$599,627	$48,167

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS PARENTHETICALS (USD $)	Aug. 31, 2013	Nov. 30, 2012
Common Stock, par or stated value	$0.00	$0.00
Common Stock, shares authorized	1,750,000,000	1,750,000,000
Common Stock, shares issued	51,144,621	49,117,903
Common Stock, shares outstanding	51,144,621	49,117,903

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended		63 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
RESEARCH AND DEVELOPMENT EXPENSES	$226,935	$542,267	$930,487	$1,740,697	$3,239,298
GENERAL AND ADMINISTRATIVE EXPENSES	935,228	1,346,807	2,844,350	1,876,966	5,661,771
OPERATING LOSS	1,162,163	1,889,074	3,774,837	3,617,663	8,901,069
FINANCIAL EXPENSE (INCOME), NET	-224,723	-13,820	49,046	-13,731	58,630
NET LOSS AND COMPREHENSIVE LOSS FOR THE PERIOD	$937,440	$1,875,254	$3,823,883	$3,603,932	$8,959,699
BASIC AND DILUTED LOSS PER COMMON STOCK	$0.02	$0.04	$0.08	$0.06
WEIGHTED AVERAGE NUMBER OF SHARES USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER COMMON STOCK:	51,144,621	48,786,381	50,264,348	56,063,918

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		63 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($3,823,883)	($3,603,932)	($8,959,699)
Adjustments required to reconcile net loss to net cash used in operating activities:
Write-off of website development costs	0	0	15,000
Stock based compensation related to options granted to employees	1,882,761	2,139,260	4,859,683
Stock-based compensation related to options granted to consultants	242,161	122,513	484,216
Depreciation	2,404	856	3,809
Change in fair value of warrants liabilities	-51,802	0	-51,802
Interest expenses due to loan	73,525	0	73,525
Increase in accrued severance pay, net	1,922	922	3,475
Receipt on account of Shares due to services rendered	6,144	509,622	515,766
Changes in operating assets and liabilities:
Increase in prepaid expenses and accounts receivable	-12,621	-25,722	-40,870
Increase in accounts payable	15,552	51,222	151,343
Increase in accrued expenses	93,889	0	167,027
Increase in related parties	0	6,862	42,362
Increase in employees and related payables	45,435	49,395	121,314
Net cash used in operating activities	-1,524,513	-749,002	-2,614,851
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	-7,839	-9,678	-17,517
Website development costs	0	0	-15,000
Investment in short term deposits	0	0	-10,002
Amounts funded in respect of retirement benefits obligations	-1,561	-677	-2,857
Net cash used in investing activities	-9,400	-10,355	-45,376
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Warrants and shares issued for cash	1,800,000	1,071,661	2,926,661
Proceeds from loan received and warrants issued for cash	250,000	0	250,000
Net cash provided by financing activities	2,050,000	1,071,661	3,176,661
INCREASE IN CASH AND CASH EQUIVALENTS	516,087	312,304	516,434
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	347	1,275	0
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$516,434	$313,579	$516,434

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' CAPITAL EQUITY/DEFICIENCY (USD $)	Common Stock [Member]	Additional paid-in capital [Member]	Deficit accumulated during the development stage [Member]	Total
Beginning Balance at Jun. 05, 2008
Shares issued to founder on June 5, 2008 $0.000357 Per Share	$5,600	$14,400		$20,000
Shares issued to founder on June 5, 2008 $0.000357 Per Share (Shares)	56,000,000
Private Placement at 0.00143$ Per Share	2,450	32,550		35,000
Private Placement at 0.00143$ Per Share (Shares)	24,500,000
Net loss for the period- Comprehensive loss			-65,321	-65,321
Ending Balance at Nov. 30, 2010	8,050	46,950	-65,321	-10,321
Ending Balance (Shares) at Nov. 30, 2010	80,500,000
Net loss for the period- Comprehensive loss			-72,352	-72,352
Ending Balance at Nov. 30, 2011	8,050	46,950	-137,673	-82,673
Beginning Balance (Shares) at Nov. 30, 2011	80,500,000
Shares cancelled	-3,387	3,387
Shares cancelled (Shares)	-33,873,049
Warrants and shares issued for cash, net of issuance expenses	110	1,071,551		1,071,661
Warrants and shares issued for cash, net of issuance expenses (Shares)	1,100,000
Stock based compensation related to options granted to employees		2,976,922		2,976,922
Stock-based compensation related to options granted to consultant		242,055		242,055
Shares issued for services	139	509,483		509,622
Shares issued for services (Shares)	1,390,952
Net loss for the period- Comprehensive loss			-4,998,143	-4,998,143
Ending Balance at Nov. 30, 2012	4,912	4,850,348	-5,135,816	-280,556
Ending Balance (Shares) at Nov. 30, 2012	49,117,903
Shares issued for cash	202	666,988		667,190
Shares issued for cash (shares)	2,026,718
Stock based compensation related to options granted to employees		1,882,761		1,882,761
Stock-based compensation related to options granted to consultant		242,161		242,161
Receipts on account of Shares		6,144		6,144
Net loss for the period- Comprehensive loss			-3,823,883	-3,823,883
Ending Balance at Aug. 31, 2013	$5,114	$7,648,402	($8,959,699)	($1,306,183)
Ending Balance (Shares) at Aug. 31, 2013	51,144,621

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Aug. 31, 2013
SIGNIFICANT ACCOUNTING POLICIES [Text Block]	NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:
		a.	General:
			Orgenesis Inc. (formerly Business Outsourcing Services, Inc.) (“the Company”), incorporated in the state of Nevada on June 5, 2008 is currently developing a new technology for regeneration of functional insulin-producing cells, thus, enabling normal glucose regulated insulin secretion, via cell therapy.
			On August 31, 2011, the Company changed its name from “Business Outsourcing Services, Inc.” to “Orgenesis Inc.”, by way of merger with its wholly-owned subsidiary Orgenesis Inc., which was formed solely for the change of name.
			On October 11, 2011, the Company incorporated a wholly-owned subsidiary in Israel, Orgenesis Ltd. (the “Israeli Subsidiary”), which is engaged in research and development. On July 31, 2013, the Company incorporated a wholly-owned subsidiary in Maryland Orgenesis Inc. (the “US Subsidiary”), which will be engaged in research and development. The US subsidiary has not commenced its operation yet.
			Unless the context indicates otherwise, the term “Group” refers to Orgenesis Inc. and its subsidiaries, Orgenesis Ltd (the “Israeli Subsidiary”) and Orgenesis Inc. (the “US Subsidiary” in Maryland)
			On February 2, 2012, the Subsidiary entered into an agreement with Tel Hashomer Medical Research, Infrastructure and Services Ltd (the “Licensor”). The Subsidiary was granted a worldwide royalty bearing, exclusive license to certain information regarding a molecular and cellular approach directed at converting liver cells into functional insulin producing cells, as treatment for diabetes.
			The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with ASC Topic 915 “Development Stage Entities”.
		b.	Basis Of Presentation
			The accompanying unaudited interim condensed consolidated financial statements as of August 31, 2013 have been prepared in accordance with accounting principles generally accepted in the United States. Accordingly, they do not include all the information and footnotes required for annual financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair statement have been included. The accounting principles applied in the preparation of the interim statements are consistent with those applied in the preparation of the annual financial statements; however, the interim statements do not include all the information and explanations required for the annual financial statements. The condensed consolidated balance sheet data as of November 30, 2012 was derived from the Company’s audited financial statements, but does not include all disclosures required by generally accepted accounting principles. For additional information, including the Company’s significant accounting policies, refer to the consolidated financial statements and related footnotes in the Company’s fiscal 2012 Annual Report on Form 10-K. Operating results for the nine months ended August 31, 2013, are not necessarily indicative of the results that be expected for the year ending November 30, 2013.
		c.	Going concern considerations
			The accompanying unaudited interim condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has stock holders' deficiency in a total amount of $1,306,183 and net losses for the period from inception (June 5, 2008) through August 31, 2013, of $8,959,699 as well as a negative cash flow from operating activities. Presently, the Company does not have sufficient cash resources to meet its plans in the twelve months following August 31, 2013. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management is in the process of evaluating various financing alternatives, as the Company will need to finance future research and development activities and general and administrative expenses through fund raising in the public or private equity markets. Although there is no assurance that the Company will be successful with those initiatives, management believes that it will be able to secure the necessary financing as a result of ongoing financing discussions with third party investors and existing shareholders.
			These consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to obtain additional financing as may be required and ultimately to attain profitability.
		d.	Warrants issued as part of capital raisings that are classified as a liability
			Warrants that entitle the holder to down-round protection (through ratchet and anti-dilution provisions) are classified as liabilities in the statement of financial position. The liability is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net. See note 5.
		e.	Fair value measurement:
			Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:
			Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
			Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
			Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
			As of August 31, 2013 the assets or liabilities measured at Level 3 fair value comprise of warrants. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent.
		f.	Newly issued and recently adopted Accounting Pronouncements
			1	In June 2011, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (ASU) 2011-05, an update to ASC No. 220, “Presentation of Comprehensive Income,” which eliminates the option to present other comprehensive income and its components in the statement of shareholders’ equity. The Company can elect to present the items of net income and other comprehensive income in a single continuous statement of comprehensive income or in two separate, but consecutive, statements. Under either method the statement would need to be presented with equal prominence as the other primary financial statements. The amended guidance, which must be applied retroactively, is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, with earlier adoption permitted. In December 2011, the FASB issued another update on the topic, which deferred the effective date pertaining only to the presentation of reclassification adjustments on the face of the financial statements. The Company adopted the pronouncement in the annual financial statements as of November 30, 2012.
			2	In February 2013, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). This update requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, ASU 2013-02 requires presentation, either on the face of the income statement or in the notes, of significant amounts reclassified out of accumulated other comprehensive income by respective line items of net income, but only if the amounts reclassified are required to be reclassified in their entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about these amounts. The amendments in ASU 2013-02 will be effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. ASU 2013-02 is effective for the Company on November 30, 2013. The Company does not expect the adoption of ASU 2013-02 to have a material effect on the consolidated financial statement presentation.

COMMITMENTS

COMMITMENTS	9 Months Ended
	Aug. 31, 2013
COMMITMENTS [Text Block]	NOTE 2 - COMMITMENTS:
		1	On February 2, 2012 the Subsidiary entered into a licensing agreement with the Licensor. According to the agreement, the Subsidiary was granted a worldwide royalty bearing, exclusive license to certain information regarding a molecular and cellular approach directed at converting liver cells into functional insulin producing cells, as treatment for diabetes.
			As consideration for the Licensed Information (as defined), the Subsidiary will pay the following to the Licensor:
			a.	A royalty of 3.5% of net sales.
			b.	16% of all sublicensing fees received.
			c.	An annual license fee of $15,000, which commenced on January 1, 2012 and shall be paid once every year thereafter (the “Annual Fee”). The Annual Fee is non-refundable, but it shall be credited each year due, against the royalty noted above, to the extent that such are payable, during that year.
			d.	Milestone payments as follows:
		1	$50,000 on the date of initiation of phase I clinical trials in human subjects;
		2	$50,000 on the date of initiation of phase II clinical trials in human subjects;
		3	$150,000 on the date of initiation of phase III clinical trials in human subjects;
		4	$750,000 on the date of initiation of issuance of an approval for marketing of the first Product by the FDA.
		5	$2,000,000, when worldwide net sales of Products have reached the amount of $150,000,000 for the first time, (The “Sales Milestone”).
	In the event of closing of an acquisition of all of the issued and outstanding share capital of the Subsidiary of the Company and/or consolidation of the Subsidiary or the Company into or with another corporation (“Exit”), the Licensor shall be entitled to choose whether to receive from the Company a one-time payment based, as applicable, on the value of either 5,563,809 shares of Common Stock of the Company at the time of the Exit or the value of 1,000 shares of common stock of the Subsidiary at the time of the Exit.
		2	On February 2, 2012 the Company entered into an agreement with Mintz, Levin, Ferris, Glovsky and Popeo, P.c. (“Mintz, Levin”) for professional services related to the patent registration. In addition to an amount of $80,000 paid to this service provider, the Company issued 1,390,952 shares of common stock that will be held in escrow for two years. As a result of the escrow, the fair value of these shares issued for services were $509,622 based on a 34.57% discount calculated, on the price per share on February 2, 2012. The Company will pay an additional $50,000 upon consummation of the earlier of:
			1	The purchase of all the Company's common shares and/or amalgamation of the company or the Subsidiary into or with another Corporation.
			2	The Company sublicensing the technology to a non-affiliate of the Company.
			3	$20,000 upon each of the following milestones (but in any event no more than $50,000 in total):
				1	Initiation by the Company of phase I clinical trials for the Company's product in human subjects.
				2	Initiation by the Company of phase II clinical trials in human subjects.
				3	Initiation by the Company of phase III clinical trials in human subjects.
		3	On February 2, 2012, the Company entered into a consultancy agreement with Weinberg Dalyo Inc, for financial consulting services for a consideration of $3,000 per month. During the period of this agreement, if the consultant locates an investor, which the Company enters into a binding investment agreement, the consultant is entitled to a bonus of 1.5% from the total investment in cash.
		4	On February 2, 2012, the Subsidiary entered into an employment agreement (the “Ferber Employment Agreement”) with Prof. Sarah Ferber. Pursuant to the Ferber Employment Agreement, Prof. Ferber agrees to serve as our Chief Scientific Officer. Prof. Ferber will be paid a gross salary of NIS (Israeli shekel) 36,000 per month, which is approximately $9,961 based on an exchange rate of 1 NIS equals $0.2767 as of August 31, 2013. In the event we complete a financing of at least $1,000,000 (in addition to the $1.5 million private placement in February 2012), Prof. Ferber’s salary will double. On May 6 2013, the Company has completed the financing of over $1,000,000, therefore.
			Prof. Ferber will be paid a gross salary of NIS (Israeli shekel) 72,000 per month, which is approximately $19,923 based on an exchange rate of 1 NIS equals $0.2767 as of August 31, 2013.
		5	On February 2, 2012, the Subsidiary entered into a compensation agreement (the “Caplan Compensation Agreement”) with Ms. Caplan. Pursuant to the Caplan Compensation Agreement, Ms. Caplan agrees to serve as a director of our company. Ms. Caplan will be paid a gross salary of NIS (Israeli shekel) 10,000 per month, which is approximately $2,767 based on an exchange rate of 1 NIS equals $0.2767 as of August 31, 2013.
			In the event we complete a financing of at least $2,000,000, Ms. Caplan will be paid a onetime bonus of $100,000. On May 6, 2013 the Company completed the financing of over $2,000,000. Therefore the Company has recorded an expense of $100,000.
		6	On March 22, 2012 the Subsidiary entered into a research service agreement with the Licensor. According to the agreement, the Licensor will perform a study at the facilities and use the equipment and personnel of the Chaim Sheba Medical Center (the “Hospital”), for the total consideration of approximately $74,000 for a year. On May 1, 2013 the Subsidiary renewed research agreement for the total annual consideration of approximately $92,000.
		7	On April 17, 2012 the Company entered into an agreement with Yaron Adler to serve as a director in the Company's board of directors for a consideration for every board meeting on an hourly basis. In the event the Company receives an aggregate financing of at least $3,000,000 he will be entitled to a one-time payment in the amount of $15,000. See also note 4(5).
		8	On April 24, 2012 the Company entered into an agreement with Granzer Regulatory Consulting &services (Granzer) to provide services with regard to regulatory and development aspects in connection with pharmaceutical products in the area of chemistry and pharmacy , clinical and regulatory. The company shall pay for services of Granzer range of 125 - 300 Euro per hour or 2,400 Euro per day.
		9	On October 18, 2012 the Company entered into an agreement with Fraunhofer IGB to perform experiment and studies on transplants of liver cells in order to develop the manufacturing process in standards that will enable Orgenesis to use it in clinical trials. According to the agreement the company should pay per achieved phase – which are defined in the agreement – a total consideration of 260,000 Euro for all services. Under the terms of the agreement it's the company's discretion whether to conclude all the phases or only part of them.
		10	On January 7, 2013 the Company appointed a new CEO to the Company, whose compensation will consist of an annual gross salary of $180,000 and the eligibility to receive stock options, performance shares and an annual bonus at the discretion of our board of directors upon the performance as follow:
		a.	982,358 Performance Shares ( 2%) will be issued upon the completion of a fundraising.
		b.	1,473,537 Performance Shares ( 3%) will be issued as to 25% on each of the first, second, third and fourth anniversaries of the date of the employment agreement.
	As of August 31, 2013 the performance conditions describe above were not met.
		11	On March 27, 2013, the Company signed an agreement with Mintz Levin, our patent attorneys, in which 16% of the fees will be converted to shares of the Company at market price. A total of $6,144 will be converted into common shares. As of August 31, 2013 the issuance of shares has not yet occurred.
		12	On May 6, 2013 the Subsidiary entered into a Process Development Agreement with ATMI BVBA, a Belgium company which is a wholly owned subsidiary of Advanced Technology Materials, Inc. (“ATMI”), a US publicly traded Company. According to the agreement the Company and ATMI will cooperate in cell research. The Company will use ATMI's unique technology while the company will provide to ATMI the required materials for purpose of the study. According to the agreement the Company will pay per achieved phase, as defined in the agreement with total consideration of 606,500 Euro for all services.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Aug. 31, 2013
STOCKHOLDERS' EQUITY [Text Block]	Ν OTE 3 – STOCKHOLDERS' EQUITY:
		a.	Share capital
			The Company’s shares are traded on the Over-The-Counter Bulletin Board.
			On August 31, 2011, the Company affected a 35 to 1 share split. As a result the issued and outstanding capital of the Company has been increased from 2,300,000 to 80,500,000 shares of common stock with par value of $0.0001 per share. Share data and per share data have been adjusted to reflect the stock split.
			On February 2, 2012, two of the Company's shareholders have cancelled 33,873,049 shares of common stock of the Company held by them in connection with the capital raising and other changes in the capital.
		b .	Financing:
				1	In February 2012, the Company entered into a subscription agreement with Derby Management LLC (“Derby”) for the sale of 500,000 shares of the Company's common stock at a purchase price of $1.00 per share, for total consideration of $500,000. Under the agreement the subscribers committed to purchase additional 1,000,000 shares of the Company's common stock at a purchase price of $1.00 per share (the “February Warrants”). The terms of the warrants to be issued based on the following criteria. 500,000 shares will be issued for an additional consideration of $500,000, upon the earlier of: (i) the Company or its Subsidiary signing an agreement with a clinical center, and (ii) 6 months following the closing of the placement of shares. The remaining 500,000 shares will be issued for an additional consideration of $500,000 upon the feasibility of enhancement of cell propagation capability if achieved prior to February 2, 2015.
				2	In April 2012, the Company completed a private placement of $100,000 with Derby for 100,000 shares of common stock and 100,000 common stock warrants at a purchase price of $1.00 per share (the “April Warrants”).
				3	In July 2012, the Company entered into a subscription agreement with Derby for an additional 500,000 common stock and 500,000 common stock warrants at a purchase price of $1.00 per share (the “July Warrants”) for total consideration of $1.00. In connection with this agreement, the February Warrants were cancelled.
				4	In December 2012, the Company entered into a subscription agreement with Derby for the issuance of 500,000 units for a total consideration of $500,000. Each unit is comprised of one share of the Company's Common Stock and two non-transferable Common Stock warrants. Each Common Stock warrant (“December Warrants”) can be exercised into one share at a purchase price of $0.50 per warrant and is exercisable until November 30, 2014. See also Note 5.
					In connection with this agreement, the July Warrants were cancelled.
		5	In March 2013, the Company entered into a loan and warrant subscription agreement with Mediapark A.G., a Marshall Islands company (“Mediapark”). The Company received a loan (the “Loan”) in the total amount of $250,000 and issued to the investor 100,000 warrants (“March Warrant”). Each Common Stock warrant can be exercised into one share at a purchase price of $0.50 per warrant and is exercisable until March 22, 2015. See also Note 5.
			The warrants issued are detachable from the loan and classified as a liability due to down- round protection (through ratchet and anti-dilution provisions), therefore the Company allocated the proceeds from Mediapark, first to the warrants based upon the fair value of the warrants, and the residual amount of proceeds was allocated to the Loan. As of the issuance day, the fair value of the warrants was $65,192 based on Monte Carlo pricing-model. See also Note 5.
			The loan bears interest at an annual rate of 8%, which is calculated quarterly. The Loan matured on June 30, 2013. The Company has the right to extend the maturity date for an additional period of up to 90 days provided it issues an additional 100,000 warrants (“Additional Warrants”).
			If the Company has not paid the Loan in full at the maturity date or, if extended, the extended maturity date, Mediapark has the right of conversion in respect of the total outstanding amount of the Loan including accrued interest as of the conversion date into common shares, at a price per common share equal to the lower of: (1) $0.75 and (2) the value of weighted average price for the five trading days prior to the date of conversion.
			On June 30, 2013 the Company exercised its discretion to extend the maturity date of the loan to September 30, 2013. In return for extending the maturity date, the Company issued to Mediapark additional Warrants at an exercise price of $0.50 per warrant. On September 30, 2013 the Company extended the maturity date of the loan to December 31, 2013. See also note 7(1).
		6	In May 2013, the Company entered into a subscription agreement with ATMI, pursuant to which ATMI purchased 1,526,718 units at a price of $0.8515 per unit for total consideration of $1,300,000. Each Unit consists of one share of the Company's Common Stock and one Common Stock warrant. Each Common Stock warrant (“May Warrants”) can be exercised into one share at a purchase price of $1 per warrant and is exercisable until May 6, 2015. See also Note 5.

STOCK_BASED_COMPENSATION

STOCK BASED COMPENSATION	9 Months Ended
	Aug. 31, 2013
STOCK BASED COMPENSATION [Text Block]	NOTE 4 – STOCK BASED COMPENSATION
		1	Global Share Incentive Plan:
			On May 23, 2012 the Company's board of directors adopted the global share incentive plan (2012) (“Global Share Incentive Plan (2012)”). Under the Global Share Incentive Plan (2012) 12,000,000 shares of common stock have been reserved for the grant of options, which may be issued at the discretion of the Company's board of directors from time to time. Under this plan, each option is exercisable into one share of common stock of the Company.
			The options may be exercised after vesting and in accordance with the vesting schedule which will be determined by the Company's board of directors for each grant. The maximum contractual life term of the options is 10 years.
			The fair value of each stock option grant is estimated at the date of grant using the Black and Scholes option pricing model. The volatility is based on historical volatilities of companies in comparable stages as well as companies in the industry historical volatility, by statistical analysis of the daily share pricing model. The expected term is equal to the contractual life, based on management estimation for the expected dates of exercising of the options.
		2	On February 2, 2012 2,781,905 options were granted to Prof. Sara Ferber, the Company's Chief Scientific Officer, at an exercise price of $0.0001 per share. The options vest in twelve equal monthly installments from the date of grant and expire on February 2, 2022 .The fair value of these options on the date of grant was $1,557,867 using the Black and Scholes option-pricing model.
		3	On February 2, 2012, 2,781,905 options were granted to Mr Jacob BenArie, the CEO of Orgenesis Ltd, at an exercise price of $0.69 per share, the options vest in twelve equal quarterly installments from the date of grant and expire on February 2, 2022. The fair value of these options as of the date of grant was $1,404,819 using the Black and Scholes option-pricing model.
		4	On June 4, 2012, 471,200 options were granted to Mr. Guy Yachin, the Company's member of the board of directors, at an exercise price of $0.85 per share, the options vest in five equal annual instalments from the date of grant and expire on June 4, 2022. The fair value of these options as of the date of grant was $363,478 using the Black and Scholes option-pricing model.
		5	On July 8, 2012, 706,890 options were granted to Mr. Yaron Eldar, the Company's member of the board of directors, at an exercise price of $0.79 per share, the options vest in five equal annual instalments from the date of grant and expire on July 8, 2022. The fair value of these options as of the date of grant was $506,635 using the Black and Scholes option-pricing model.
		6	On July 10, 2012, 3,338,285 options were granted to Ms. Caplan, the Company's Chairperson of the Board at an exercise price of $0.001 per share, the options vest in two equal annual instalments from the date of grant and expire on February 2, 2022. The fair value of these options as of the date of grant was $2,935,496 using the Black and Scholes option-pricing model.
		7	On July 8, 2012, 235,630 options were granted to Ms. Etti Hanochi, the Company's member of the board of directors, at an exercise price of $0.79 per share, the options vest in five equal annual instalments from the date of grant and expire on July 8, 2022. The fair value of these options as of the date of grant was $171,207 using the Black and Scholes option-pricing model.
		8	On July 16, 2013 250,000 options were granted to Dr David Sidransky , the Company's member of the board of directors at an exercise price of $0.75 per share, the options vest in five equal annual installments from the date of grant and expire on July 16, 2023. The fair value of these options as of the date of grant was $167,561 using the Black and Scholes option-pricing model.
			The fair value of each option grant is estimated on the date of grant using the Black Scholes option-pricing model with the following assumptions:
		For options
		granted until
		August 30,
		2013
	Expected option life (years)	10
	Expected stock price volatility (%)	98 - 105
	Risk free interest rate (%)	1.53 - 1.86
	Expected dividend yield (%)	0
	A summary of the Company's stock option granted to employees and directors as of August 31, 2013 and changes for the nine months ended August 31, 2012 is presented below:
							Nine months ended
				31-Aug-13					31-Aug-12
							Weighted			Weighted
				Number			average		Number	average
				Of			exercise		of	exercise
				Options			price		options	price
							$			$
		Options outstanding at the beginning of the year		10,315,815			0.297		-	-
		Changes during the period:
		Granted - at market price		250,000			0.75		10,315,815	0.186
		Expired		-			-		-	-
		Options outstanding at end of the period		10,565,815			0.313		10,315,815	0.186
		Options exercisable at end of the period		4,455,602			0.27		1,854,603	0.172
	Costs incurred in respect of stock based compensation for employees and directors, for the nine months ended August 31, 2013 and August 31, 2012 were $1,882,761 and $2,139,260, respectively. The weighted average period of the remaining unearned compensation of $2,247,380 at August 31, 2013 will be recorded over 2.3 years.
	The following table presents summary information concerning the options granted to employees outstanding as of August 31, 2013:
					Weighted average
			Number of		remaining		Weighted average
	Exercise		outstanding		contractual		Exercise	Aggregate
	price		options		Life		price	intrinsic value
	$				Years		$	$
	0.0001		2,781,905		8.42		0.0001	2,086,151
	0.001		3,338,285		8.42		0.001	2,500,375
	0.69		2,781,905		8.42		0.69	166,914
	0.75		250,000		9.87		0.75	-
	0.79		942,520		8.85		0.79	-
	0.85		471,200		8.76		0.85	-
			10,565,815		8.51		0.31	4,753,440
	The following table presents summary of information concerning the options exercisable as of August 31, 2013:
			Number of		Weighted
	Exercise		Exercisable		Average
	price		options		Exercise price
	$				$
	0.0001		2,781,905		278
	0.69		1,390,953		959,757
	0.79		188,504		148,918
	0.85		94,240		80,104
			4,455,602		1,189,058
	Options granted to non-employees:
		1	On April 14, 2012, 471,200 options were granted to Dr. G. Alexander (Zan) Fleming, the Company's advisor, at an exercise price of $1.40 per share, the options vest five equal annual instalments from the date of grant and expire on April 14, 2022. The fair value of these options as of the date of grant is $564,907 using the Black and Scholes option-pricing model.
		2	On June 4, 2012, 706,904 options were granted to Mr. Dov Weinberg, the Company's CFO, at an exercise price of $0.69 per share, the options vest in four equal semi - annual installments from February 2, 2012 and expire on February 2, 2022. The fair value of these options as of the date of grant is $500,678 using the Black and Scholes option-pricing model.
		3	On November 21, 2012, 100,000 options were granted to Camillo Ricordi, a consultant for the Company, at an exercise price of $0.61 per share, the options vest in five equal annual installments from the date of grant and expire on November 21, 2022. The fair value of these options as of the date of grant is $64,513 using the Black and Scholes option-pricing model.
		4	On August 2, 2013 100,000 options were granted to Prof. Skyler , one of the Company's advisory board, at an exercise price of $0.96 per share, the options vest in five equal annual installments from the date of grant and expire on April 4, 2023. The fair value of these options as of the date of grant was $65,620 using the Black and Scholes option-pricing model.
The fair value of each option grant is estimated on the date of grant using the Black Scholes option-pricing model with the following assumptions:
	For options granted
	until
	August 31,
	2013
Expected option life (years)	10
Expected stock price volatility (%)	98 - 110
Risk free interest rate (%)	1.53 - 2.78
Expected dividend yield (%)	0
A summary of the status of the stock options granted to non-employees as of August 31, 2013 and August 31, 2012 and changes for the nine months ended is presented below:
			Nine months ended
			31-Aug-13					31-Aug-12
						Weighted			Weighted
			Number			average		Number	average
			Of			exercise		of	exercise
			Options			price		options	price
						$			$
	Options outstanding at beginning of year		1,278,104			0.95		-	-
	Changes during the year:
	Granted - at market price		100,000			0.96		1,178,104	0.97
	Expired							-	-
	Options outstanding at end of the period		1,378,104			0.94		1,178,104	0.97
	Options exercisable at end of the period		624,418			0.8		176,726	0.69
Costs incurred in respect of stock based compensation for consultants, for the nine months ended August 31, 2013 and August 31, 2012 were $242,161 and $122,513 respectively. The weighted average period of the remaining unearned compensation of $423,417 as of August 31, 2013 will be recorded over 3.11 years. The following table presents summary information concerning the options granted to non-employees outstanding as of August 31, 2013:
				Weighted
				average		Weighted
		Number of		Remaining		Average
Exercise		Outstanding		Contractual		Exercise	Aggregate
prices		options		Life		Price	intrinsic value
$				Years			$
0.61		100,000		9.22		0.61	14,000
0.69		706,904		8.42		0.69	42,414
0.96		100,000		9.59		0.96	-
1.4		471,200		8.62		1.4	-
		1,378,104		8.63		0.942	56,414
The following table presents summary of information concerning the options exercisable as of August 31, 2013:
		Number of
Exercise		Exercisable			Total
prices		options			Exercise price
					$
0.69		530,178			365,822
1.4		94,240			131,936
		624,418			497,758

WARRANTS

WARRANTS	9 Months Ended
	Aug. 31, 2013
WARRANTS [Text Block]	NOTE 5- WARRANTS
	As part of the Company's private placements as described in note 3 the Company issued to the investors warrants, as follows:
		1	In December 2012, the Company issued 1,000,000 non-transferable Common Stock warrants. Each Common Stock warrant (“December Warrants”) can be exercised into one share at an exercise price of $0.50 per warrant and is exercisable until November 30, 2014. In the event the Company will issue any Common Stock or securities convertible into the Common Stock at a price less than the purchase price of the Warrants, the price shall be reduced to the new issuance price.
			As of February 28, 2013, the December Warrants were presented within stockholders’ equity. After further review, the Company has determined that these instruments should have been classified as liabilities. Changes in the fair value of these Warrants require adjustments to the amount of the liabilities recorded on the Company's balance sheet, and the corresponding gain or loss is required to be recorded in the Company's statement of comprehensive loss.
			In March 2013 the Company issued 100,000 warrants (“March Warrant”) in connection with the agreements with Mediapark. Each Common Stock warrant can be exercised into one share at an exercise price of $0.50 per warrant and is exercisable until March 22, 2015. In the event the Company will issue any Common Stock or securities convertible into the Common Stock at a price less than the purchase price of the Warrants, the price shall be reduced to the new issuance price.
		2	In May 2013, the Company issued 1,526,718 warrants (“May Warrants”). Each Common Stock warrant can be exercised into one share at an exercise price of $1 per warrant and is exercisable until May 6, 2015. In the event the Company will issue any Common Stock or securities convertible into the Common Stock at a price less than $0.8515, the price shall be reduced to the new issuance price.
		3	On June 30, 2013 the company exercised its discretion to extend the maturity date of the Mediapark Loan to September 30, 2013. In return for extending the maturity date, the Company issued to Mediapark 100,000 additional Warrants at an exercise price of $0.5. For additional information see Note 3b5.
	The fair value of each of the warrants described above, as determined by using a Monte Carlo type model based on a risk neutral approach. The model takes as an input the estimated future dates when new capital will be raised, and builds a multi-step dynamic model. The first step is to model the risk neutral distribution of the share value on the new issue dates, then for each path to use the Black-Scholes model to estimate the value of the warrants on the last issue date including all the changes in exercise price and quantity along this path. The significant unobservable input used in the fair value measurement is the future expected issue dates. Significant delay in this input would result a higher fair value measurement.
	Financial liabilities carried at fair value as of August 31, 2013 are classified in the tables below in one of the three fair value categories:
			Fair value measurements at reporting
			date using
			Level 3			Total
	Warrants -
	31-Aug-13	$	1,161,956		$	1,161,956
	The following table summarizes the activity for those financial liabilities where fair value measurements are estimated utilizing Level 3 inputs:
				During the nine			During the three
				months ended			months ended
				August 31,			August 31,
				2013			2013
		Carrying value at the beginning of the period	$	-		$	1,402,530
		Additions	$	1,245,270			47,268
		Changes in fair value of warrant liabilities		(83,314	)		(287,842	)
		Carrying value at the end of the period
			$	1,161,956		$	1,161,956

TAXES_ON_INCOME

TAXES ON INCOME	9 Months Ended
	Aug. 31, 2013
TAXES ON INCOME [Text Block]	NOTE 6 – TAXES ON INCOME
		1	Corporate taxation in the U.S.
			The applicable corporate tax rate for the Company is 34%.
		2	Corporate taxation in Israel:
			The Subsidiary is taxed in accordance with Israeli tax laws. The regular corporate tax rate in Israel for 2013 is 25%.
		3	Deferred income taxes:
			As of			As of
			August 31,			November 30,
			2013			2012
	In respect of:
	Net operating loss carry forward	$	749,424		$	344,307
	R&D expenses		123,584			57,344
	Holiday and recreation pay		10,806			3,968
	Severance pay accruals		869			402
	Less – Valuation allowance		(884,683	)		(406,021	)
	Net deferred tax assets	$	-		$	-
	Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carryforwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a full valuation allowance.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Aug. 31, 2013
SUBSEQUENT EVENTS [Text Block]	NOTE 7 - SUBSEQUENT EVENTS
		1	On September 30, 2013 the Company extended the maturity date of the loan to December 31, 2013 in return for extending the maturity date the Company issued to Mediapark 100,000 Additional Warrants. See also note 3b5.
		2	On October 11, 2013 Orgenesis Ltd. established a wholly-owned subsidiary in Belgium, Orgenesis SPRL, which will be engaged in development and manufacturing activities together with the clinical studies in Europe.

Summary_of_Significant_Account

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Aug. 31, 2013
General [Policy Text Block]		a.	General:
			Orgenesis Inc. (formerly Business Outsourcing Services, Inc.) (“the Company”), incorporated in the state of Nevada on June 5, 2008 is currently developing a new technology for regeneration of functional insulin-producing cells, thus, enabling normal glucose regulated insulin secretion, via cell therapy.
			On August 31, 2011, the Company changed its name from “Business Outsourcing Services, Inc.” to “Orgenesis Inc.”, by way of merger with its wholly-owned subsidiary Orgenesis Inc., which was formed solely for the change of name.
			On October 11, 2011, the Company incorporated a wholly-owned subsidiary in Israel, Orgenesis Ltd. (the “Israeli Subsidiary”), which is engaged in research and development. On July 31, 2013, the Company incorporated a wholly-owned subsidiary in Maryland Orgenesis Inc. (the “US Subsidiary”), which will be engaged in research and development. The US subsidiary has not commenced its operation yet.
			Unless the context indicates otherwise, the term “Group” refers to Orgenesis Inc. and its subsidiaries, Orgenesis Ltd (the “Israeli Subsidiary”) and Orgenesis Inc. (the “US Subsidiary” in Maryland)
			On February 2, 2012, the Subsidiary entered into an agreement with Tel Hashomer Medical Research, Infrastructure and Services Ltd (the “Licensor”). The Subsidiary was granted a worldwide royalty bearing, exclusive license to certain information regarding a molecular and cellular approach directed at converting liver cells into functional insulin producing cells, as treatment for diabetes.
			The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with ASC Topic 915 “Development Stage Entities”.
Basis Of Presentation [Policy Text Block]		b.	Basis Of Presentation
			The accompanying unaudited interim condensed consolidated financial statements as of August 31, 2013 have been prepared in accordance with accounting principles generally accepted in the United States. Accordingly, they do not include all the information and footnotes required for annual financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair statement have been included. The accounting principles applied in the preparation of the interim statements are consistent with those applied in the preparation of the annual financial statements; however, the interim statements do not include all the information and explanations required for the annual financial statements. The condensed consolidated balance sheet data as of November 30, 2012 was derived from the Company’s audited financial statements, but does not include all disclosures required by generally accepted accounting principles. For additional information, including the Company’s significant accounting policies, refer to the consolidated financial statements and related footnotes in the Company’s fiscal 2012 Annual Report on Form 10-K. Operating results for the nine months ended August 31, 2013, are not necessarily indicative of the results that be expected for the year ending November 30, 2013.
Going concern considerations [Policy Text Block]		c.	Going concern considerations
			The accompanying unaudited interim condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has stock holders' deficiency in a total amount of $1,306,183 and net losses for the period from inception (June 5, 2008) through August 31, 2013, of $8,959,699 as well as a negative cash flow from operating activities. Presently, the Company does not have sufficient cash resources to meet its plans in the twelve months following August 31, 2013. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management is in the process of evaluating various financing alternatives, as the Company will need to finance future research and development activities and general and administrative expenses through fund raising in the public or private equity markets. Although there is no assurance that the Company will be successful with those initiatives, management believes that it will be able to secure the necessary financing as a result of ongoing financing discussions with third party investors and existing shareholders.
			These consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to obtain additional financing as may be required and ultimately to attain profitability.
Warrants issued as part of capital raisings that are classified as a liability [Policy Text Block]		d.	Warrants issued as part of capital raisings that are classified as a liability
			Warrants that entitle the holder to down-round protection (through ratchet and anti-dilution provisions) are classified as liabilities in the statement of financial position. The liability is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net. See note 5.
Fair value measurement [Policy Text Block]		e.	Fair value measurement:
			Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:
			Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
			Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
			Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
			As of August 31, 2013 the assets or liabilities measured at Level 3 fair value comprise of warrants. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent.
Newly issued and recently adopted Accounting Pronouncements [Policy Text Block]		f.	Newly issued and recently adopted Accounting Pronouncements
			1	In June 2011, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (ASU) 2011-05, an update to ASC No. 220, “Presentation of Comprehensive Income,” which eliminates the option to present other comprehensive income and its components in the statement of shareholders’ equity. The Company can elect to present the items of net income and other comprehensive income in a single continuous statement of comprehensive income or in two separate, but consecutive, statements. Under either method the statement would need to be presented with equal prominence as the other primary financial statements. The amended guidance, which must be applied retroactively, is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, with earlier adoption permitted. In December 2011, the FASB issued another update on the topic, which deferred the effective date pertaining only to the presentation of reclassification adjustments on the face of the financial statements. The Company adopted the pronouncement in the annual financial statements as of November 30, 2012.
			2	In February 2013, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”). This update requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, ASU 2013-02 requires presentation, either on the face of the income statement or in the notes, of significant amounts reclassified out of accumulated other comprehensive income by respective line items of net income, but only if the amounts reclassified are required to be reclassified in their entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about these amounts. The amendments in ASU 2013-02 will be effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. ASU 2013-02 is effective for the Company on November 30, 2013. The Company does not expect the adoption of ASU 2013-02 to have a material effect on the consolidated financial statement presentation.

STOCK_BASED_COMPENSATION_Table

STOCK BASED COMPENSATION (Tables)	9 Months Ended
	Aug. 31, 2013
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]		For options
		granted until
		August 30,
		2013
	Expected option life (years)	10
	Expected stock price volatility (%)	98 - 105
	Risk free interest rate (%)	1.53 - 1.86
	Expected dividend yield (%)	0
Schedule of Stock Options Granted to Employees and Directors [Table Text Block]							Nine months ended
				31-Aug-13					31-Aug-12
							Weighted			Weighted
				Number			average		Number	average
				Of			exercise		of	exercise
				Options			price		options	price
							$			$
		Options outstanding at the beginning of the year		10,315,815			0.297		-	-
		Changes during the period:
		Granted - at market price		250,000			0.75		10,315,815	0.186
		Expired		-			-		-	-
		Options outstanding at end of the period		10,565,815			0.313		10,315,815	0.186
		Options exercisable at end of the period		4,455,602			0.27		1,854,603	0.172
Schedule of Information Stock Options Granted to Employees and Directors [Table Text Block]					Weighted average
			Number of		remaining		Weighted average
	Exercise		outstanding		contractual		Exercise	Aggregate
	price		options		Life		price	intrinsic value
	$				Years		$	$
	0.0001		2,781,905		8.42		0.0001	2,086,151
	0.001		3,338,285		8.42		0.001	2,500,375
	0.69		2,781,905		8.42		0.69	166,914
	0.75		250,000		9.87		0.75	-
	0.79		942,520		8.85		0.79	-
	0.85		471,200		8.76		0.85	-
			10,565,815		8.51		0.31	4,753,440
Schedule of Disclosure of Share-based Compensation Stock Options Exercisable [Table Text Block]			Number of		Weighted
	Exercise		Exercisable		Average
	price		options		Exercise price
	$				$
	0.0001		2,781,905		278
	0.69		1,390,953		959,757
	0.79		188,504		148,918
	0.85		94,240		80,104
			4,455,602		1,189,058
Schedule of Fair Value of Stock Options Granted Valuation Assumptions [Table Text Block]		For options granted
		until
		August 31,
		2013
	Expected option life (years)	10
	Expected stock price volatility (%)	98 - 110
	Risk free interest rate (%)	1.53 - 2.78
	Expected dividend yield (%)	0
Schedule of Stock Options Granted to Non-Employees [Table Text Block]				Nine months ended
				31-Aug-13					31-Aug-12
							Weighted			Weighted
				Number			average		Number	average
				Of			exercise		of	exercise
				Options			price		options	price
							$			$
		Options outstanding at beginning of year		1,278,104			0.95		-	-
		Changes during the year:
		Granted - at market price		100,000			0.96		1,178,104	0.97
		Expired							-	-
		Options outstanding at end of the period		1,378,104			0.94		1,178,104	0.97
		Options exercisable at end of the period		624,418			0.8		176,726	0.69
Schedule of Information Options Granted to Non-Employees [Table Text Block]					Weighted
					average		Weighted
			Number of		Remaining		Average
	Exercise		Outstanding		Contractual		Exercise	Aggregate
	prices		options		Life		Price	intrinsic value
	$				Years			$
	0.61		100,000		9.22		0.61	14,000
	0.69		706,904		8.42		0.69	42,414
	0.96		100,000		9.59		0.96	-
	1.4		471,200		8.62		1.4	-
			1,378,104		8.63		0.942	56,414
Schedule of Stock Options Exercisable [Table Text Block]			Number of
	Exercise		Exercisable			Total
	prices		options			Exercise price
						$
	0.69		530,178			365,822
	1.4		94,240			131,936
			624,418			497,758

WARRANTS_Tables

WARRANTS (Tables)	9 Months Ended
	Aug. 31, 2013
Schedule of Financial liabilities carried at fair value [Table Text Block]			Fair value measurements at reporting
			date using
			Level 3			Total
	Warrants -
	31-Aug-13	$	1,161,956		$	1,161,956
Schedule of Activity fo fair value measurements of financial liabilities [Table Text Block]				During the nine			During the three
				months ended			months ended
				August 31,			August 31,
				2013			2013
		Carrying value at the beginning of the period	$	-		$	1,402,530
		Additions	$	1,245,270			47,268
		Changes in fair value of warrant liabilities		(83,314	)		(287,842	)
		Carrying value at the end of the period
			$	1,161,956		$	1,161,956

TAXES_ON_INCOME_Tables

TAXES ON INCOME (Tables)	9 Months Ended
	Aug. 31, 2013
Schedule of Deferred Tax Assets [Table Text Block]			As of			As of
			August 31,			November 30,
			2013			2012
	In respect of:
	Net operating loss carry forward	$	749,424		$	344,307
	R&D expenses		123,584			57,344
	Holiday and recreation pay		10,806			3,968
	Severance pay accruals		869			402
	Less – Valuation allowance		(884,683	)		(406,021	)
	Net deferred tax assets	$	-		$	-

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
Significant Accounting Policies 1	$1,306,183
Significant Accounting Policies 2	$8,959,699

COMMITMENTS_Narrative_Details

COMMITMENTS (Narrative) (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
Commitments 1	3.50%
Commitments 2	16.00%
Commitments 3	$15,000
Commitments 4	50,000
Commitments 5	50,000
Commitments 6	150,000
Commitments 7	750,000
Commitments 8	2,000,000
Commitments 9	150,000,000
Commitments 10	5,563,809
Commitments 11	1,000
Commitments 12	80,000
Commitments 13	1,390,952
Commitments 14	509,622
Commitments 15	34.57%
Commitments 16	50,000
Commitments 17	20,000
Commitments 18	50,000
Commitments 19	3,000
Commitments 20	1.50%
Commitments 21	36,000
Commitments 22	9,961
Commitments 23	1
Commitments 24	0.2767
Commitments 25	1,000,000
Commitments 26	1,500,000
Commitments 27	1,000,000
Commitments 28	72,000
Commitments 29	19,923
Commitments 30	1
Commitments 31	0.2767
Commitments 32	10,000
Commitments 33	2,767
Commitments 34	1
Commitments 35	0.2767
Commitments 36	2,000,000
Commitments 37	100,000
Commitments 38	2,000,000
Commitments 39	100,000
Commitments 40	74,000
Commitments 41	92,000
Commitments 42	3,000,000
Commitments 43	15,000
Commitments 44	125
Commitments 45	300
Commitments 46	2,400
Commitments 47	260,000
Commitments 48	180,000
Commitments 49	982,358
Commitments 50	2.00%
Commitments 51	1,473,537
Commitments 52	3.00%
Commitments 53	25.00%
Commitments 54	16.00%
Commitments 55	$6,144
Commitments 56	606,500

STOCKHOLDERS_EQUITY_Narrative_

STOCKHOLDERS' EQUITY (Narrative) (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
	D
	M
Stockholders' Equity 1	35
Stockholders' Equity 2	1
Stockholders' Equity 3	2,300,000
Stockholders' Equity 4	80,500,000
Stockholders' Equity 5	$0.00
Stockholders' Equity 6	33,873,049
Stockholders' Equity 7	500,000
Stockholders' Equity 8	$1
Stockholders' Equity 9	$500,000
Stockholders' Equity 10	1,000,000
Stockholders' Equity 11	$1
Stockholders' Equity 12	500,000
Stockholders' Equity 13	500,000
Stockholders' Equity 14	6
Stockholders' Equity 15	500,000
Stockholders' Equity 16	500,000
Stockholders' Equity 17	100,000
Stockholders' Equity 18	100,000
Stockholders' Equity 19	100,000
Stockholders' Equity 20	$1
Stockholders' Equity 21	500,000
Stockholders' Equity 22	500,000
Stockholders' Equity 23	$1
Stockholders' Equity 24	1
Stockholders' Equity 25	500,000
Stockholders' Equity 26	500,000
Stockholders' Equity 27	$0.50
Stockholders' Equity 28	250,000
Stockholders' Equity 29	100,000
Stockholders' Equity 30	$0.50
Stockholders' Equity 31	65,192
Stockholders' Equity 32	8.00%
Stockholders' Equity 33	90
Stockholders' Equity 34	100,000
Stockholders' Equity 35	0.75
Stockholders' Equity 36	$0.50
Stockholders' Equity 37	1,526,718
Stockholders' Equity 38	$0.85
Stockholders' Equity 39	$1,300,000
Stockholders' Equity 40	$1

STOCK_BASED_COMPENSATION_Narra

STOCK BASED COMPENSATION (Narrative) (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
	Y
Stock Based Compensation 1	12,000,000
Stock Based Compensation 2	10
Stock Based Compensation 3	2,781,905
Stock Based Compensation 4	$0.00
Stock Based Compensation 5	$1,557,867
Stock Based Compensation 6	2,781,905
Stock Based Compensation 7	$0.69
Stock Based Compensation 8	1,404,819
Stock Based Compensation 9	471,200
Stock Based Compensation 10	$0.85
Stock Based Compensation 11	363,478
Stock Based Compensation 12	706,890
Stock Based Compensation 13	$0.79
Stock Based Compensation 14	506,635
Stock Based Compensation 15	3,338,285
Stock Based Compensation 16	$0.00
Stock Based Compensation 17	2,935,496
Stock Based Compensation 18	235,630
Stock Based Compensation 19	$0.79
Stock Based Compensation 20	171,207
Stock Based Compensation 21	250,000
Stock Based Compensation 22	$0.75
Stock Based Compensation 23	167,561
Stock Based Compensation 24	1,882,761
Stock Based Compensation 25	2,139,260
Stock Based Compensation 26	2,247,380
Stock Based Compensation 27	2.3
Stock Based Compensation 28	471,200
Stock Based Compensation 29	$1.40
Stock Based Compensation 30	564,907
Stock Based Compensation 31	706,904
Stock Based Compensation 32	$0.69
Stock Based Compensation 33	500,678
Stock Based Compensation 34	100,000
Stock Based Compensation 35	$0.61
Stock Based Compensation 36	64,513
Stock Based Compensation 37	100,000
Stock Based Compensation 38	$0.96
Stock Based Compensation 39	65,620
Stock Based Compensation 40	242,161
Stock Based Compensation 41	122,513
Stock Based Compensation 42	$423,417
Stock Based Compensation 43	3.11

WARRANTS_Narrative_Details

WARRANTS (Narrative) (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
Warrants 1	1,000,000
Warrants 2	$0.50
Warrants 3	100,000
Warrants 4	$0.50
Warrants 5	1,526,718
Warrants 6	$1
Warrants 7	$0.85
Warrants 8	100,000
Warrants 9	$0.50

TAXES_ON_INCOME_Narrative_Deta

TAXES ON INCOME (Narrative) (Details)	9 Months Ended
	Aug. 31, 2013
Taxes On Income 1	34.00%
Taxes On Income 2	25.00%

SUBSEQUENT_EVENTS_Narrative_De

SUBSEQUENT EVENTS (Narrative) (Details)	9 Months Ended
	Aug. 31, 2013
Subsequent Events 1	100,000

Schedule_of_Sharebased_Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 1	10
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 2	$98
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 3	$105
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 4	1.53
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 5	1.86
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 6	0

Schedule_of_Stock_Options_Gran

Schedule of Stock Options Granted to Employees and Directors (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 1	$10,315,815
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 2	0.297
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 3	0
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 4	0
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 5	250,000
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 6	0.75
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 7	10,315,815
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 8	0.186
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 9	0
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 10	0
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 11	0
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 12	0
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 13	10,565,815
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 14	0.313
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 15	10,315,815
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 16	0.186
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 17	4,455,602
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 18	0.27
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 19	$1,854,603
Stock Based Compensation Schedule Of Stock Options Granted To Employees And Directors 20	0.172

Schedule_of_Information_Stock_

Schedule of Information Stock Options Granted to Employees and Directors (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 1	0.0001
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 2	$2,781,905
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 3	8.42
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 4	0.0001
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 5	2,086,151
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 6	0.001
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 7	3,338,285
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 8	8.42
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 9	0.001
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 10	2,500,375
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 11	0.69
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 12	2,781,905
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 13	8.42
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 14	0.69
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 15	166,914
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 16	0.75
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 17	250,000
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 18	9.87
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 19	0.75
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 20	0
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 21	0.79
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 22	942,520
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 23	8.85
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 24	0.79
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 25	0
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 26	0.85
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 27	471,200
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 28	8.76
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 29	0.85
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 30	0
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 31	10,565,815
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 32	8.51
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 33	0.31
Stock Based Compensation Schedule Of Information Stock Options Granted To Employees And Directors 34	$4,753,440

Schedule_of_Disclosure_of_Shar

Schedule of Disclosure of Share-based Compensation Stock Options Exercisable (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 1	0.0001
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 2	$2,781,905
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 3	278
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 4	0.69
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 5	1,390,953
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 6	959,757
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 7	0.79
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 8	188,504
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 9	148,918
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 10	0.85
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 11	94,240
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 12	80,104
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 13	4,455,602
Stock Based Compensation Schedule Of Disclosure Of Share-based Compensation Stock Options Exercisable 14	$1,189,058

Schedule_of_Fair_Value_of_Stoc

Schedule of Fair Value of Stock Options Granted Valuation Assumptions (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 1	10
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 2	$98
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 3	$110
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 4	1.53
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 5	2.78
Stock Based Compensation Schedule Of Fair Value Of Stock Options Granted Valuation Assumptions 6	0

Schedule_of_Stock_Options_Gran1

Schedule of Stock Options Granted to Non-Employees (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 1	$1,278,104
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 2	0.95
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 3	0
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 4	0
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 5	100,000
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 6	0.96
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 7	1,178,104
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 8	0.97
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 9	0
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 10	0
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 11	1,378,104
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 12	0.94
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 13	1,178,104
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 14	0.97
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 15	624,418
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 16	0.8
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 17	$176,726
Stock Based Compensation Schedule Of Stock Options Granted To Non-employees 18	0.69

Schedule_of_Information_Option

Schedule of Information Options Granted to Non-Employees (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 1	0.61
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 2	$100,000
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 3	9.22
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 4	0.61
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 5	14,000
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 6	0.69
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 7	706,904
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 8	8.42
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 9	0.69
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 10	42,414
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 11	0.96
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 12	100,000
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 13	9.59
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 14	0.96
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 15	0
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 16	1.4
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 17	471,200
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 18	8.62
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 19	1.4
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 20	0
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 21	1,378,104
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 22	8.63
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 23	0.942
Stock Based Compensation Schedule Of Information Options Granted To Non-employees 24	$56,414

Schedule_of_Stock_Options_Exer

Schedule of Stock Options Exercisable (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
Stock Based Compensation Schedule Of Stock Options Exercisable 1	0.69
Stock Based Compensation Schedule Of Stock Options Exercisable 2	$530,178
Stock Based Compensation Schedule Of Stock Options Exercisable 3	365,822
Stock Based Compensation Schedule Of Stock Options Exercisable 4	1.4
Stock Based Compensation Schedule Of Stock Options Exercisable 5	94,240
Stock Based Compensation Schedule Of Stock Options Exercisable 6	131,936
Stock Based Compensation Schedule Of Stock Options Exercisable 7	624,418
Stock Based Compensation Schedule Of Stock Options Exercisable 8	$497,758

Schedule_of_Financial_liabilit

Schedule of Financial liabilities carried at fair value (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
Warrants Schedule Of Financial Liabilities Carried At Fair Value 1	$1,161,956
Warrants Schedule Of Financial Liabilities Carried At Fair Value 2	$1,161,956

Schedule_of_Activity_fo_fair_v

Schedule of Activity fo fair value measurements of financial liabilities (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
Warrants Schedule Of Activity Fo Fair Value Measurements Of Financial Liabilities 1	$0
Warrants Schedule Of Activity Fo Fair Value Measurements Of Financial Liabilities 2	1,402,530
Warrants Schedule Of Activity Fo Fair Value Measurements Of Financial Liabilities 3	1,245,270
Warrants Schedule Of Activity Fo Fair Value Measurements Of Financial Liabilities 4	47,268
Warrants Schedule Of Activity Fo Fair Value Measurements Of Financial Liabilities 5	-83,314
Warrants Schedule Of Activity Fo Fair Value Measurements Of Financial Liabilities 6	-287,842
Warrants Schedule Of Activity Fo Fair Value Measurements Of Financial Liabilities 7	1,161,956
Warrants Schedule Of Activity Fo Fair Value Measurements Of Financial Liabilities 8	$1,161,956

Schedule_of_Deferred_Tax_Asset

Schedule of Deferred Tax Assets (Details) (USD $)	9 Months Ended
	Aug. 31, 2013
Taxes On Income Schedule Of Deferred Tax Assets 1	$749,424
Taxes On Income Schedule Of Deferred Tax Assets 2	344,307
Taxes On Income Schedule Of Deferred Tax Assets 3	123,584
Taxes On Income Schedule Of Deferred Tax Assets 4	57,344
Taxes On Income Schedule Of Deferred Tax Assets 5	10,806
Taxes On Income Schedule Of Deferred Tax Assets 6	3,968
Taxes On Income Schedule Of Deferred Tax Assets 7	869
Taxes On Income Schedule Of Deferred Tax Assets 8	402
Taxes On Income Schedule Of Deferred Tax Assets 9	-884,683
Taxes On Income Schedule Of Deferred Tax Assets 10	-406,021
Taxes On Income Schedule Of Deferred Tax Assets 11	0
Taxes On Income Schedule Of Deferred Tax Assets 12	$0